Skip to main content
. Author manuscript; available in PMC: 2008 Oct 24.
Published in final edited form as: Oncogene. 2008 Apr 7;27(31):4315–4323. doi: 10.1038/onc.2008.65

Figure 5.

Figure 5

YY1 induction of the EGFR promoter is potentiated by p53 RNAi, and mutations in the p53 binding sites on the EGFR promoter do not alter YY1-mediated induction. (a) Normal HKc were transiently co-transfected with the pGL3-EGFR promoter construct (1 μg per well) and the YY1 expression vector or its control pcDNA 3.1 plasmid (500 ng per well), along with p53RNAi-1 or its control, the pSuper plasmid (1 μg per well) and pRL-Null (10 ng per well). Cells were harvested 48 h post-transfection for dual-luciferase assays. (b) Normal HKc were transiently co-transfected with wild-type pGL3-EGFR promoter construct or EGFR promoter constructs containing mutations in the p53 binding sites (1.5 μg per well), the YY1 expression plasmid or its pcDNA 3.1 control vector (10 ng per well) and pRL-Null (10 ng per well). Cells were harvested 48 h post-transfection for dual-luciferase assays. EGFR, epidermal growth factor receptor; HKc, human keratinocytes; YY1, Yin Yang 1.